OCREVUS
As listed in the register: OCREVUS 920 MG SOLUCION INYECTABLE
920 mg · solución inyectable
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Ocrelizumab
- Made by
- Roche Registration Gmbh
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (OCREVUS). It describes the substance, not this exact product.
The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes.
Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-05-14
Safety of the active substance
From the US prescribing label for the same active substance (OCREVUS). It describes the substance, not this exact product.
- OCREVUS is contraindicated in patients with: Active HBV infection [see Dosage and Administration (2.1) and Warnings and Precautions (5.2) ] A history of life-threatening infusion reaction to OCREVUS [see Warnings and Precautions (5.1) ] Active hepatitis B virus infection ( 4 ) History of life-threatening infusion reaction to OCREVUS ( 4 )
The most common adverse reactions in RMS trials (incidence ≥ 10%) were upper respiratory tract infections and infusion reactions.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
Netherlands1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Roche Registration Gmbh |
|---|---|
| Active substance | Ocrelizumab |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 920 mg |
| Form | solución inyectable |
| Classification | L04AG08 · Cancer treatments and immune-system medicines |
| Route | vía subcutánea |
| Marketed | No — authorised but not currently marketed, according to the register |
| Name in the register | OCREVUS 920 MG SOLUCION INYECTABLE |
| Nº Registro | 1171231003 |
Source: CIMA — Centro de Información online de Medicamentos · 2026-09-30 · not reviewed by a clinician
Fuente: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA. Reuse terms: Aviso legal AEMPS.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solución inyectable1 products
- 920 mg
- concentrado para solución para perfusión1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.